The Opioid Quota Openness, Transparency, and Awareness (QuOTA) Act of 2019 (S 1366, 116th Congress) would require the Department of Justice to publicly publish opioid manufacturers’ procurement quotas through the Drug Enforcement Administration’s website. In the Act, “opioid procurement quota” is defined as the quantity of opioid analgesics that manufacturers can obtain in order to manufacture other dosages or substances from these opioids. The Act specifies that the following information would be made publicly available:
- The number specified as the opioid procurement quota for each manufacturer every year;
- The number of opioid analgesics obtained by these manufacturers;
- The manufacturer’s opioid procurement quota application; and
- The manufacturer’s year-end report of the procurement of opioid analgesics.
The Department of Justice would be granted the ability to excuse manufacturers from disclosing their application and year-end report in the case that this would involve trade secrets or other privileged information.
The public has paid recent attention to the role that opioid manufacturers played in the ongoing opioid crisis. Notably, one company — Purdue Pharma — that developed and manufactured the opioid OxyContin has been involved in several lawsuits that allege the company and its top executives knowingly misled the public and healthcare providers about the dangers associated with their product.